采用慢病毒载体干扰TRAF2表达的MH7A细胞稳转株的构建及意义  

Significance and successful construction of stable transfection of MH7A cells with lower TRAF2 expression using lentiviral vector

作　　者：陈露颖 蒋励萍 王伟康 左书俊 蒯佳婕 马旸[1] 韩陈陈 魏伟[1] Chen Luying;Jiang Liping;Wang Weikang;Zuo Shujun;Kuai Jiajie;Ma Yang;Han Chenchen;Wei Wei(Institute of Clinical Pharmacology,Anhui Medical University,Key Laboratory of Anti inflammatory and Immune Drugs of the Ministry of Education,Anhui Collaborative Innovation Center for Anti inflammatory and Immune Drugs,Hefei 230032)

机构地区：[1]安徽医科大学临床药理研究所、抗炎免疫药物教育部重点实验室、抗炎免疫药物安徽省协同创新中心,合肥230032

出　　处：《安徽医科大学学报》2024年第2期193-199,共7页Acta Universitatis Medicinalis Anhui

基　　金：国家自然科学基金(编号:82104187、82173824、81973332);安徽省自然科学基金(编号:2108085QH382);中国博士后科学基金(编号:2021T140002、2021M700184);安徽省博士后基金(编号:2020B430)。

摘　　要：目的 用慢病毒载体构建干扰肿瘤坏死因子受体相关因子2(TRAF2)表达的类风湿关节炎(RA)患者滑膜细胞株MH7A细胞稳转株,研究TNF-α-TRAF2信号在MH7A异常增殖的作用。方法 根据人TRAF2的基因序列和shRNA序列设计原则,设计并合成3对TRAF2-shRNA干扰序列,通过PCR对引物进行退火,通过双酶切PLKO.1-puro获得线性载体,将线性化载体与退火后引物通过Solution I连接,连接产物导入感受态细胞,涂板,挑取阳性菌落进行测序。构建3种不同的PLKO.1-TRAF2-shRNA慢病毒重组质粒,借助慢病毒包装质粒对对数生长期的HEK 293T细胞进行慢病毒包装,收集病毒液感染MH7A细胞,同时使用嘌呤霉素对TRAF2低表达的MH7A稳转株进行筛选。使用CCK-8法、Western blot、qPCR检测MH7A中肿瘤坏死因子TNF-α诱导TRAF2低表达的MH7A增殖功能及下游信号TRAF2、P65蛋白表达和mRNA水平。结果 成功构建了PLKO.1-TRAF2-shRNA(1)、PLKO.1-TRAF2-shRNA(2)和PLKO.1-TRAF2-shRNA(3)慢病毒载体质粒和对照组慢病毒载体质粒PLKO.1-puro,将3个TRAF2-shRNA慢病毒载体质粒和对照组慢病毒载体质粒PLKO.1-puro分别与慢病毒包装质粒导入HEK 293T获得病毒液,将病毒液感染MH7A细胞后,经嘌呤霉素(2.00μg/ml)筛选,2 d得到MH7A稳转株;qPCR和Western blot结果显示,PLKO.1-TRAF2-shRNA(1) MH7A细胞稳转株中TRAF2 mRNA和蛋白的表达较阴性对照组明显下降;CCK-8和Western blot结果表明,MH7A中TRAF2敲低后,TNF-α诱导的TRAF2低表达的MH7A细胞增殖和P65的磷酸化水平明显下降。结论 成功构建了PLKO.1-TRAF2-shRNA(1) MH7A细胞稳转株,研究TNF-α-TRAF2信号活化介导RA滑膜细胞异常增殖中的作用。Objective To construct a stable synovial cell line MH7A from rheumatoid arthritis(RA) patients using lentiviral vectors that interfere with the expression of tumor necrosis factor receptor associated factor 2(TRAF2),and to study the role of TNF-α-TRAF2 signaling in MH7A abnormal proliferation.Methods Based on the design principles of human TRAF2 gene sequence and shRNA sequence,three pairs of TRAF2 shRNA interference sequences were designed and synthesized.The primers were annealed by PCR,and a linear vector was obtained by double enzyme digestion PLKO.1-puro.The linearized vector was connected to the annealed primers through Solution I,and the connected products were introduced into receptive cells.The plates were coated,and positive colonies were selected for sequencing.Three different recombinant plasmids of PLKO.1-TRAF2-shRNA lentivirus were constructed,and lentivirus packaging plasmids was used to package logarithmic growth phase HEK 293T cells.Virus solution was collected to infect MH7A cells.At the same time,puromycin was used to screen MH7A stable transgenic strains with low TRAF2 expression.CCK-8 method,Western blot,and qPCR were used to detect the proliferation function of MH7A induced by TNF-α and low expression of TRAF2,as well as downstream signal TRAF2,P65 protein expression and mRNA levels.Results PLKO.1-TRAF2-shRNA(1),PLKO.1-TRAF2-shRNA(2),and PLKO.1-TRAF2-shRNA(3) lentivirus vector plasmids and control group lentivirus vector plasmids PLKO.1-puro were successfully constructed.The three TRAF2-shRNA lentivirus vector plasmids and control group lentivirus vector plasmids PLKO.1-puro were respectively introduced into the lentivirus packaging plasmid of HEK 293T to obtain virus solution.After infecting MH7A cells with the virus solution,they were treated with puromycin(2.00 μ G/mL) screening and obtaining MH7A stable transgenic plants after 2 days.Through qPCR and Western blot results,it was found that the expression of TRAF2 mRNA and protein in PLKO.1-TRAF2-shRNA(1) MH7A stably transfected cells w

关 键 词：类风湿关节炎 MH7A 肿瘤坏死因子受体相关因子2 慢病毒载体 

分 类 号：R34[医药卫生—基础医学]